Project Grant P01CA298963
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $290,017.00 to St. Jude Children's Research Hospital Inc. to investigate the cell state hierarchy and transcriptional/epigenetic determinants of therapy-resistant progenitor-like cells in fusion-negative rhabdomyosarcoma (FN-RMS), a type of pediatric soft tissue sarcoma. The award will support computational and experimental research approaches, including single-cell RNA sequencing,...
- This Project Grant award for $1,340,665.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The award supports research focused on the FGFR pathway as a lead therapeutic vulnerability in pediatric ependymoma, a type of brain cancer in children. The project will be conducted over 3 years, from September 1, 2023 to August 31, 2026, and aims to advance the development of effective...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to St. Jude Children's Research Hospital Inc. provides $718,113 to fund research on "Targetable Epigenetic Modifiers that Promote Neuroblastoma Malignancy and Plasticity". The project aims to investigate how epigenetic factors, including histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), connect the MYC oncogenes to neuroblastoma-specific...
- This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Beckman Research Institute of the City of Hope to investigate the role of IL-6/STAT3 signaling in the progression and metastasis of CIC-DUX4 fusion-positive sarcomas. The $593,028 award, effective April 3, 2025 through March 31, 2030, will fund studies to determine whether targeting the IL-6/STAT3 pathway can block tumor growth, metastasis, and immunosuppression...
- This federal Project Grant award for $226,608.00 was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) grant program. The award supports research conducted by St. Jude Children's Research Hospital Inc. to investigate the mechanism by which a specific gene regulates chromatin function and its implications for the viability of rhabdoid tumors. The research aims to elucidate how the loss of this gene further disrupts the balance between the SWI/SNF chromatin...
- This federal Project Grant award of $134,757.00, provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research to identify therapeutic vulnerabilities of chromosome 3 rearranged myeloid leukemias. The overall objective is to develop and apply novel proteogenomic approaches to study these aggressive blood cancers, which currently lack targeted precision therapies and have dismal 5-year survival rates. The award will fund research...
- The U.S. National Cancer Institute (NCI) awarded a $1,049,120 Project Grant to St. Jude Children's Research Hospital Inc. through the Cancer Biology Research federal grant program (CFDA 93.396). The project aims to "Dissect Neomorphic Functions Mediated by Mutant-Specific Structures of SPOP", with the goal of understanding how cancer-related mutations in the SPOP protein affect its structure and function to drive tumor development. The research will leverage the awardee's recent...
- This federal Project Grant award of $667,480.00 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to St. Jude Children's Research Hospital Inc. The award supports fundamental scientific research and advanced training focused on understanding the regulation of genome expression by chromatin and how mutations in chromatin proteins contribute to oncogenesis. The research aims to provide new insights...